Endocrine Abstracts

Background: Recent studies show that Infliximab (IFX), an antibody against tumour necrosis factor α (TNFα), may improve growth in children with Crohn’s disease (CD). These studies have not adequately addressed the concomitant factors such as medication, nutrition and puberty that may also improve growth.Methods: Retrospective study of 22 children (13 M) with CD, median age at start of IFX 13.2 years (7.4, 16.1) with auxology at 6 months be...

Background: Growth retardation and pubertal delay is frequently encountered in children with inflammatory bowel disease (IBD). There are currently no published data on sitting height (SH), subischial leg length (SILL)and growth rates in relation to pubertal status in these children.Objective: To assess skeletal disproportion and growth rates in children with IBD.Methods: Retrospective study of 40 children (32M):35 Crohn’s dise...

Background: Recent studies show that infliximab (IFX), an antibody against tumour necrosis factorα (TNFα), may improve growth in children with Crohn’s disease (CD). These studies have not adequately addressed the concomitant factors such as medication, nutrition and puberty that may also improve growth.Methods: Retrospective study of 22 children (13M) with CD, median age at start of IFX 13.2 years (7.4, 16.1) with auxology at 6 months befo...